Open access
Open access
Powered by Google Translator Translator

Infectious Diseases (all articles)

Study finds increased risk of pulmonary embolism up to 110 days after COVID-19.

7 Apr, 2022 | 10:06h | UTC

Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study – The BMJ

News Release: Study finds increased risk of serious blood clots up to six months after COVID-19 – BMJ

Editorial: Thromboembolism and bleeding after covid-19

Commentary: Covid: Blood clot risk higher for six months after having virus – BBC

 

M-A: Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization.

7 Apr, 2022 | 09:55h | UTC

Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis – JAMA Network Open

Commentary: Common Antidepressant Likely Cuts Risk Of Covid Hospitalization, Study Finds – Forbes

Related:

Short Review: Fluvoxamine for symptomatic outpatients with COVID-19.

Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

 

Commentary on Twitter

 

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines.

7 Apr, 2022 | 10:00h | UTC

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines –
European Centre for Disease Prevention and Control

Related:

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Commentary on Twitter (thread – click for more)

 

Pragmatic RCT: In outpatients with Covid-19, the addition of pulse oximetry for monitoring did not improve outcomes compared to subjective assessments of dyspnea alone.

7 Apr, 2022 | 09:58h | UTC

Pulse Oximetry for Monitoring Patients with Covid-19 at Home — A Pragmatic, Randomized Trial – New England Journal of Medicine

 

Commentary on Twitter

 

RCT: Among patients with complicated urinary tract infection, oral Tebipenem Pivoxil Hydrobromide was noninferior to intravenous Ertapenem and showed a similar safety profile.

7 Apr, 2022 | 09:53h | UTC

Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 

Perspective | Studying severe long COVID to understand post-infectious disorders beyond COVID-19.

7 Apr, 2022 | 08:45h | UTC

Studying severe long COVID to understand post-infectious disorders beyond COVID-19 – Nature Medicine

Related:

Review: Post-acute COVID-19 syndrome.

ESCMID rapid guidelines for assessment and management of long COVID.

ERS statement on Long COVID-19 follow-up.

Proposed subtypes of long-Covid and their respective potential therapies.

EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play.

Review | Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus.

The pathogenesis and long-term consequences of Covid-19 cardiac injury: state-of-the-art review.

COVID-19 infections increase risk of heart conditions up to a year later, study finds.

 

Commentary from the author on Twitter (thread – click for more)

 

Perspective | An equitable roadmap for ending the COVID-19 pandemic.

7 Apr, 2022 | 08:48h | UTC

An equitable roadmap for ending the COVID-19 pandemic – Nature Medicine

 

Commentary on Twitter

 

WHO Strategic framework for collaboration on antimicrobial resistance.

7 Apr, 2022 | 08:41h | UTC

Strategic framework for collaboration on antimicrobial resistance – World Health Organization

Related:

Four priority actions to slow the silent pandemic of antimicrobial resistance.

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.

Perspective | The hidden epidemic: Antibiotic resistance is approaching a crisis point, and the world needs to act.

 

Commentary on Twitter

 

Expert Consensus: Stepwise diagnostic approach for patients with uveitis.

7 Apr, 2022 | 07:53h | UTC

Step-wise diagnostic approach for patients with uveitis – Experts consensus in Taiwan – Journal of Microbiology, Immunology and Infection

 

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

6 Apr, 2022 | 10:59h | UTC

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel – New England Journal of Medicine

Commentary: Mixed Bag for Fourth Dose of Pfizer Vaccine vs Omicron— Real-world data show less infection and severity, but long-term benefit less clear – MedPage Today (free registration required)

Related:

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Commentary on Twitter

 

Retrospective cohort study: Waning COVID-19 vaccine effectiveness for Pfizer and CoronaVac in Malaysia.

6 Apr, 2022 | 10:57h | UTC

Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study – International Journal of Infectious Diseases

 

Commentary on Twitter

 

Cohort Study: Incidence rates and clinical outcomes of SARS-CoV-2 infection with the Omicron and Delta variants in children younger than 5 years in the US.

6 Apr, 2022 | 10:52h | UTC

Incidence Rates and Clinical Outcomes of SARS-CoV-2 Infection With the Omicron and Delta Variants in Children Younger Than 5 Years in the US – JAMA Pediatrics

Commentary: Omicron ‘less severe’ than Delta for children ages 4 and younger, study suggests – Case Western Reserve University

 

Commentary on Twitter

 

RCT: Cabotegravir (intramuscular injections every 8 weeks) for the prevention of HIV-1 in women.

6 Apr, 2022 | 10:51h | UTC

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial – The Lancet (link to abstract – $ for full-text)

Related:

FDA approves first injectable treatment for HIV pre-exposure prevention.

RCT: Injectable long-acting Cabotegravir for HIV prevention in cisgender men and transgender women.

 

Review and M-A: pulmonary rehabilitation for Post-Covid.

6 Apr, 2022 | 10:42h | UTC

Study 1: The effectiveness of pulmonary rehabilitation for Post-COVID symptoms: A rapid review of the literature – Respiratory Medicine

Study 2: Effect of Pulmonary Rehabilitation for Patients With Post-COVID-19: A Systematic Review and Meta-Analysis – Frontiers in Medicine

 

Consensus Statement: Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis.

5 Apr, 2022 | 09:54h | UTC

Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India – The Lancet Infectious Diseases

 

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

5 Apr, 2022 | 09:46h | UTC

The Evidence On 4th Doses of Covid Vaccines & the Thorny Question of Age Thresholds – Absolutely Maybe Blog, by Hilda Bastian

Related:

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Commentary on Twitter

https://twitter.com/hildabast/status/1509724907965665280

 

Cohort Study: Change in heart disease and stroke mortality before and during the Covid-19 pandemic.

5 Apr, 2022 | 08:47h | UTC

Age-Adjusted Mortality Rates and Age and Risk–Associated Contributions to Change in Heart Disease and Stroke Mortality, 2011-2019 and 2019-2020 – JAMA Network Open

Commentaries:

Several-Fold Increase in Stroke and Heart Disease Deaths During COVID-19 Pandemic – NeurologyToday

2019 to 2020 Saw Risk-Linked Deaths From Heart Disease, Stroke Up – HealthDay

 

Commentary from the author on Twitter (thread – click for more). Article and images under CC-BY License

 

RCT: Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D).

5 Apr, 2022 | 08:50h | UTC

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India – The Lancet

Invited Commentary: DNA vaccines join the fight against COVID-19 – The Lancet

 

Commentary on Twitter

 

Systematic Review: Timing of antibiotic administration, wound debridement, and the stages of reconstructive surgery for open long bone fractures of the upper and lower limbs.

5 Apr, 2022 | 08:08h | UTC

Timing of antibiotic administration, wound debridement, and the stages of reconstructive surgery for open long bone fractures of the upper and lower limbs – Cochrane Library

Summary: The timing of treatment for broken bones in the legs and arms that also have open wounds – Cochrane Library

 

Review: Tackling the emerging threat of antifungal resistance to human health.

5 Apr, 2022 | 08:02h | UTC

Tackling the emerging threat of antifungal resistance to human health – Nature Reviews Microbiology (if the link is paywalled, try this one)

 

WHO Strategic preparedness, readiness and response plan to end the global Covid-19 emergency in 2022.

4 Apr, 2022 | 01:44h | UTC

Strategic Preparedness, Readiness and Response Plan to End the Global COVID-19 Emergency in 2022 – World Health Organization

 

Commentary on Twitter (thread – click for more)

 

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge (deliberately infecting individuals in a controlled environment) in young adults.

4 Apr, 2022 | 01:27h | UTC

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults – Nature Medicine

Commentaries:

Understanding COVID-19 through human challenge models – Nature Medicine

First human challenge study of Covid-19 yields valuable insights about how we get sick – CNN

First Human Challenge Trial Shows How COVID-19 Strikes – HealthDay

Related:

Scientists deliberately gave people COVID — here’s what they learnt.

[Preprint] Results from the first Covid-19 human challenge study (deliberately infecting individuals in a controlled environment).

Perspective | SARS-CoV-2 human challenge studies — establishing the model during an evolving pandemic.

World’s first coronavirus “Human Challenge” study receives ethics approval in the UK  (several texts on the subject)

Are SARS-CoV-2 Human Challenge Trials Ethical? – “A clinical trial is underway in the UK in which young, healthy participants are exposed deliberately to SARS-CoV-2 to assess the viral inoculum needed to produce an infection and to test vaccine efficacy”.

 

Commentary on Twitter

 

RCT: Higher dose primaquine more effective for preventing relapse of Plasmodium vivax Malaria compared to standard dose.

4 Apr, 2022 | 01:25h | UTC

Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria – New England Journal of Medicine

 

Commentaries on Twitter

 

Two new studies show vaccination provides additional protection after Covid-19 infection.

4 Apr, 2022 | 01:16h | UTC

Study 1: Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden – The Lancet Infectious Diseases

Study 2: Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study – The Lancet Infectious Diseases

Commentaries:

Interplay of infection and vaccination in long-term protection from COVID-19 – The Lancet Infectious Diseases

Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world – The Lancet Infectious Diseases

Vaccines offer substantial extra protection after COVID-19 infection – CIDRAP

Had COVID? Getting Vaccine Boosts Resilience Even More, Studies Show – HealthDay

Related:

Retrospective cohort study: Pfizer vaccine reduces the risk of reinfection after recovery from Covid-19.

Cohort study: Protection against SARS-CoV-2 after Covid-19 vaccination lasts longer in patients with previous infection.

 

Commentary on Twitter (thread – click for more)

 

WHO launches global initiative to tackle deadly insect-borne ‘arboviruses’.

4 Apr, 2022 | 00:57h | UTC

WHO launches Global Initiative to Tackle Deadly Insect-Borne ‘Arboviruses’ – Health Policy Watch

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.